SG Americas Securities LLC Buys 6,425 Shares of Illumina, Inc. $ILMN

SG Americas Securities LLC boosted its stake in Illumina, Inc. (NASDAQ:ILMN) by 8.0% during the 1st quarter, Holdings Channel reports. The firm owned 86,318 shares of the life sciences company’s stock after buying an additional 6,425 shares during the quarter. SG Americas Securities LLC’s holdings in Illumina were worth $10,640,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Elyxium Wealth LLC bought a new stake in shares of Illumina in the fourth quarter worth about $25,000. Board of the Pension Protection Fund bought a new position in Illumina during the fourth quarter valued at $26,000. Creative Capital Management Investments LLC grew its stake in shares of Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after buying an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. purchased a new position in shares of Illumina in the 4th quarter worth $26,000. Finally, Laurel Wealth Advisors LLC bought a new stake in shares of Illumina in the 4th quarter worth about $26,000. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $176.55 on Friday. The company has a market capitalization of $26.71 billion, a price-to-earnings ratio of 32.10, a PEG ratio of 3.32 and a beta of 1.50. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $182.84. The firm’s 50-day moving average is $149.62 and its 200 day moving average is $137.66. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Research analysts predict that Illumina, Inc. will post 5.21 EPS for the current year.

Analyst Ratings Changes

ILMN has been the topic of several recent research reports. Weiss Ratings upgraded shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. Wall Street Zen cut Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Citigroup upped their price objective on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research report on Monday, May 4th. Sanford C. Bernstein assumed coverage on Illumina in a research note on Friday. They issued a “market perform” rating and a $185.00 price objective for the company. Finally, Royal Bank Of Canada assumed coverage on Illumina in a report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 target price for the company. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Illumina currently has a consensus rating of “Hold” and a consensus target price of $146.00.

Insiders Place Their Bets

In other news, SVP Patricia Leckman sold 783 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the sale, the senior vice president directly owned 21,259 shares in the company, valued at approximately $3,456,500.81. This represents a 3.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $163.63, for a total value of $38,453,050.00. Following the transaction, the director owned 2,830,452 shares of the company’s stock, valued at approximately $463,146,860.76. The trade was a 7.67% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 1,003,769 shares of company stock valued at $155,710,908. Corporate insiders own 2.90% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.